Organon (OGN) Retained Earnings (2020 - 2026)
Organon (OGN) posted quarterly Retained Earnings of $1.4 billion for Q2 2026, up 16.25% year-over-year from $1.2 billion in Q2 2025, and up 7.9% on a QoQ basis from $1.3 billion in Q1 2026.
Organon (OGN) Retained Earnings (2020 - 2026) Analysis & Trends
Organon has reported Retained Earnings for 7 years, with the latest figure at $1.4 billion in Q2 2026.
- Retained Earnings for Q2 2026 came in at $1.4 billion, up 16.25% year-over-year; the trailing twelve-month figure through Jun 2026 was $1.4 billion (up 16.25% YoY), and the FY2025 annual result was $1.1 billion, up 9.8% from the prior year.
- Retained Earnings advanced to $1.4 billion in Q2 2026, from $1.3 billion in the prior quarter.
- Over five years, Retained Earnings peaked at $1.4 billion in Q2 2026 and troughed at -$724.0 million in Q1 2022.
- A 5-year average of $254.0 million and a median of $78.5 million in 2023 frame the typical range for Retained Earnings.
- The widest annual swing landed in 2022, when Retained Earnings sank 827.16%; it then soared 286.69% in 2024.
- A 5-year view of Retained Earnings shows it stood at -$564.0 million in 2022, then gained by 4.08% to -$541.0 million in 2023, then soared by 286.69% to $1.0 billion in 2024, then advanced by 9.8% to $1.1 billion in 2025, then increased by 21.91% to $1.4 billion in 2026.
- Per Business Quant data, the three most recent Retained Earnings figures were $1.4 billion in Q2 2026, $1.3 billion in Q1 2026, and $1.1 billion in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.40 Bn | 624.64 Bn | 17.26 Bn | 171.67 Bn |
| 2 | AbbVie | 462.79 Bn | 456.22 Bn | 12.70 Bn | -17.33 Bn |
| 3 | Merck | 369.55 Bn | 362.41 Bn | 12.21 Bn | 63.27 Bn |
| 4 | Novartis Ag | 298.79 Bn | 291.10 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 255.57 Bn | 250.67 Bn | 12.86 Bn | 12.59 Bn |
| 6 | Amgen | 233.87 Bn | 219.89 Bn | 7.24 Bn | -22.28 Bn |
| 7 | Gilead Sciences | 179.24 Bn | 176.06 Bn | 6.22 Bn | 9.53 Bn |
| 8 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 112.09 Bn |
| 9 | Gsk | 104.53 Bn | 100.36 Bn | 8.24 Bn | 15.38 Bn |
| 10 | Organon | 3.61 Bn | 2.47 Bn | 847.00 Mn | 1.35 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.35 Bn |
| Mar 31, 2026 | 1.25 Bn |
| Dec 31, 2025 | -527.00 Mn |
| Sep 30, 2025 | -574.00 Mn |
| Jun 30, 2025 | -572.00 Mn |
| Mar 31, 2025 | 1.03 Bn |
| Dec 31, 2024 | 1.01 Bn |
| Sep 30, 2024 | 975.00 Mn |
| Jun 30, 2024 | 690.00 Mn |
| Mar 31, 2024 | -577.00 Mn |
| Dec 31, 2023 | 443.00 Mn |
| Sep 30, 2023 | -16.00 Mn |
| Jun 30, 2023 | -533.00 Mn |
| Mar 31, 2023 | -534.00 Mn |
| Dec 31, 2022 | -331.00 Mn |
| Sep 30, 2022 | -686.00 Mn |
| Jun 30, 2022 | -589.00 Mn |
| Mar 31, 2022 | -529.00 Mn |
| Dec 31, 2021 | -998.00 Mn |
| Sep 30, 2021 | -1.13 Bn |